Acumen Pharmaceuticals Nominates Two Development Candidates In Its Enhanced Brain Delivery Program For Alzheimer's Disease Treatments, IND Submission Expected In Mid-2027

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

ABOS

0.00
  • ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR Pharmaceuticals
  • EBD technology represents the only anti-amyloid oligomer program combining a validated blood-brain barrier-penetrating technology with a therapeutic antibody tested in the clinic
  • Acumen's EBD candidates are designed to achieve higher brain penetration with potential for improved safety compared to native antibodies and delivered in a stable, low volume subcutaneous administration format
  • Investigational New Drug (IND)-enabling activities are ongoing to support IND submission in mid-2027
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.